Hypothesis

NAD+ levels directly license the mitochondrial DNA replication machinery; declining NAD+ reduces the activity of SIRT1‑dependent deacetylation of mitochondrial replication factors, leading to increased mtDNA copy number instability and mutagenesis. Thus, mtDNA damage is a downstream consequence of NAD+ depletion, not an independent driver of aging.

Mechanistic reasoning

• SIRT1 deacetylates and activates TFAM and POLGα, promoting faithful mtDNA replication and nucleoid packaging. When NAD+ falls, SIRT1 activity drops, causing hyperacetylation of TFAM and POLGα, which reduces their DNA binding affinity and polymerase fidelity.
• Hypoacetylated TFAM normally coats mtDNA, protecting it from oxidative damage; hyperacetylated TFAM displaces, exposing the genome to ROS generated by the electron transport chain.
• Reduced NAD+ also impairs the mitochondrial unfolded protein response (UPR^mt) via decreased SIRT3 activity, lowering antioxidant defenses and further increasing ROS pressure on mtDNA.
• Consequently, as NAD+ declines with age, mtDNA suffers increased mutation load and copy number variance, which only becomes phenotypically relevant after a threshold of clonal expansion is reached—a process that follows, rather than precedes, the NAD+ deficit.

Testable predictions

1. Rescue of replication fidelity: Acute NAD+ restoration (e.g., NR or NMN treatment) in aged mice will increase SIRT1 activity, decrease TFAM/POLGα acetylation, and reduce newly arising mtDNA mutations measured by duplex sequencing within 4 weeks, without altering existing mutant clone frequencies.
2. Directionality of causality: Inducing a specific mtDNA mutator phenotype (POLG^mut/mut) in young mice will not lower NAD+ levels or SIRT1 activity, whereas NAD+ depletion via CD38 overexpression will recapitulate mtDNA mutation accrual even in a POLG‑wild‑type background.
3. Threshold shift: Boosting NAD+ will raise the mutant mtDNA threshold required to cause respiratory deficiency, observable as a right‑shift in the relationship between mutant load and OXPHOS capacity in single‑cell respirometry assays.
4. Lactate dissociation: Manipulating NAD+ will change mitochondrial ROS and mtDNA mutation rates without proportionally altering plasma lactate, indicating lactate reflects downstream ETC failure rather than NAD+ status directly.

Experimental approach

• Cohorts: Young (3 mo) and aged (24 mo) C57BL/6 mice; subgroups receive NR (400 mg/kg/day) or vehicle for 8 weeks.
• Readouts:
  • NAD+ quantification in liver and muscle by LC‑MS.
  • SIRT1 activity assay and western blot for acetyl‑TFAM and acetyl‑POLGα.
  • mtDNA mutation frequency via duplex sequencing of mitochondrial genomes.
  • Single‑cell OXPHOS capacity using Seahorse XF on isolated fibers.
  • Plasma lactate measured enzymatically.
  • CD38 overexpression via AAV9 in a separate young cohort to test NAD+ depletion directionality.
• Statistical plan: Power analysis targeting 80 % power to detect a 30 % change in mutation frequency (α=0.05). Two‑way ANOVA with factors age and treatment, followed by Tukey post‑hoc.

Potential outcomes and interpretation

• If NAD+ supplementation reduces new mtDNA mutations and acetylation marks without affecting pre‑existing mutant clones, it supports NAD+ as an upstream regulator of mtDNA fidelity.
• If POLG^mut/mut mice show unchanged NAD+ levels, it challenges the notion that mtDNA dysfunction drives NAD+ decline.
• Failure to observe these patterns would necessitate revisiting the hypothesis, perhaps implicating parallel pathways (e.g., NAD+‑independent ROS sources) as primary mtDNA mutagens.

Broader impact

Confirming NAD+‑dependent licensing of mtDNA replication would reposition NAD+ boosters as preservers of mitochondrial genome integrity, shifting the focus of longevity strategies from mutation‑centric models to cofactor homeostasis. It also provides a mechanistic bridge linking metabolic signaling, epigenetic regulation of mitochondrial nucleoids, and the stochastic threshold phenomenon observed in clonal mtDNA expansion.